Airtripmaker Expands Business and First-class Flights Network to London, Amsterdam, Frankfurt, Tokyo, Sydney by Introducing Enhanced Coverage for Global Destinations as Part of Its Ongoing Growth Strategy 
Castill Health Announces Plans for Philippines Digital Healthcare Launch, Supported by Craig Astill and Caason Group BioAtla Reports Second Quarter 2022 Financial Results And Highlights Recent Progress
Mecbotamab vedotin (BA3011) Phase 2 preliminary observations in Non-Small Cell Lung Carcinoma (NSCLC) supports advancing…
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2022 Financial Results
Interim Phase 1/2 results for zilovertamab plus ibrutinib in MCL presented at ASCO 2022, with…
Satsuma Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Progress in STS101 Development Program
– Completed enrollment in the SUMMIT pivotal Phase 3 efficacy trial of STS101, randomizing more…
Seer Reports Second Quarter 2022 Financial Results
Company launches novel proteogenomics workflow with the Proteograph™ Analysis Suite 2.0, further demonstrates the power…
Neoleukin Therapeutics Announces Second Quarter 2022 Financial Results & Provides Corporate Update
Company to Host Conference Call Today, August 9, 2022, at 1:30 p.m. Pacific / 4:30…
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2022 Financial Results
– More than $2.6 billion in cash, cash equivalents, investments and profit-share payments to be received…
Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress
First two RAS(ON) Inhibitor drug candidates advance into clinical development Successful equity financing supports development…
Allogene Therapeutics Reports Second Quarter 2022 Financial Results
U.S. FDA Clearance on Potential Pivotal Phase 2 Trial of ALLO-501A Anticipated in Coming Weeks…
eFFECTOR Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Presented positive interim results at ASCO 2022 from ongoing zotatifin Phase 1/2 dose escalation and…
Zentalis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Update
Strengthened leadership team with the appointment of additional industry veterans, including CEO Dr. Kimberly Blackwell…
Journey Medical Corporation Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
Second quarter 2022 net revenue increased 20% to $18.3 million versus the same quarter of…
Lumos Pharma Reports Second Quarter 2022 Financial Results and Clinical Development Updates
— Continue to Anticipate Interim Data from Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials in…
Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results
Positive topline results for CY6463 announced in two clinical studies in patients with Mitochondrial Encephalomyopathy,…
Verizon Frontline debuts THOR’s Hammer
NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) — Verizon Frontline today introduced THOR’s (Tactical Humanitarian…
Tantalus Systems Holding Inc. Reports Financial Results for Q2 of 2022
Burnaby, British Columbia–(Newsfile Corp. – August 9, 2022) – Tantalus Systems (TSX: GRID) (“Tantalus” or…
Tenet Comments on Market Activity at the Request of IIROC
Toronto, Ontario–(Newsfile Corp. – August 9, 2022) – Tenet Fintech Group Inc. (CSE: PKK) (OTC…
Summit Therapeutics Closes Fully-Subscribed $100 Million Rights Offering
Menlo Park, California, Aug. 09, 2022 (GLOBE NEWSWIRE) — Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,”…
Trethera Announces FDA Orphan Drug Designation Granted to TRE-515 for the Treatment of Demyelinating Optic Neuritis
Figure 1 Representative stained sections of the optic nerve from mice. Arrows point to regions…
InterPro Solutions and Customer Southern Company Win Award for “Best Mobility” at MaximoWorld 2022. InterPro Invited to Speak at Largest Conference Dedicated to The Maximo User Community
InterPro Solutions is lauded for their innovative Maximo mobile solution and technology leadership. AUSTIN, Texas,…
Medicenna Announces Pricing of US$20 Million Public Offering of Units
TORONTO and HOUSTON, Aug. 09, 2022 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or the “Company”)…